Intellia Therapeutics, Inc.
NTLA
$8.50
$0.4255.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.57M | 57.88M | 43.09M | 45.97M | 52.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.57M | 57.88M | 43.09M | 45.97M | 52.60M |
| Cost of Revenue | 462.89M | 466.31M | 458.42M | 448.73M | 449.80M |
| Gross Profit | -417.32M | -408.43M | -415.33M | -402.76M | -397.20M |
| SG&A Expenses | 123.75M | 125.83M | 122.38M | 121.28M | 120.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 586.64M | 592.14M | 580.79M | 570.01M | 569.94M |
| Operating Income | -541.07M | -534.26M | -537.71M | -524.05M | -517.34M |
| Income Before Tax | -525.91M | -519.02M | -522.28M | -508.80M | -485.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -525.91 | -519.02 | -522.28 | -508.80 | -485.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -525.91M | -519.02M | -522.28M | -508.80M | -485.50M |
| EBIT | -541.07M | -534.26M | -537.71M | -524.05M | -517.34M |
| EBITDA | -530.80M | -523.98M | -527.52M | -514.18M | -507.90M |
| EPS Basic | -5.23 | -5.25 | -5.45 | -5.48 | -5.37 |
| Normalized Basic EPS | -3.09 | -3.07 | -3.21 | -3.25 | -3.31 |
| EPS Diluted | -5.23 | -5.25 | -5.45 | -5.48 | -5.37 |
| Normalized Diluted EPS | -3.09 | -3.07 | -3.21 | -3.25 | -3.31 |
| Average Basic Shares Outstanding | 403.33M | 395.33M | 383.94M | 371.58M | 362.79M |
| Average Diluted Shares Outstanding | 403.33M | 395.33M | 383.94M | 371.58M | 362.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |